Mit Cannabis gegen die Volkskrankheiten


Seite 9 von 9
Neuester Beitrag: 01.07.20 18:23
Eröffnet am: 04.08.17 09:51 von: cQiz Anzahl Beiträge: 214
Neuester Beitrag: 01.07.20 18:23 von: GoldenStock Leser gesamt: 37.529
Forum: Hot-Stocks   Leser heute: 37
Bewertet mit:
3


 
Seite: < 1 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
>  

2987 Postings, 3565 Tage GoldenStockGibts Meinungen zu PREV? Kommt morgen der Knall ?

 
  
    #201
01.03.20 18:01
Könnte sich doch aufgrund der Marktlage auch was tun - viele Biotechnologie- und Forschungsunternehmen werden nächste Woche wohl gut laufen, nachdem Corono und das Gesundheitssystem als "äußerst Wichtig" künftig erachtet wird.
Könnte einen richtigen Boom bei all diesen Werten auslösen. Was meint Ihr ??
Vielleicht gehört PREV auch bald zu den Gewinnern - und wir sehen ganz andere Kursregionen ?
Viel Glück an alle.  

2987 Postings, 3565 Tage GoldenStockNews !!

 
  
    #202
29.04.20 21:18
PreveCeutical Confirms its First Peptide with Promising Pre-Clinical Efficacy as a Non-Addictive Painkiller  C.PREV | 7 hours ago

Vancouver, British Columbia--(Newsfile Corp. - April 29, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce an update to its Non-Addictive Analgesic (dynorphin pain peptide) Program.

Following the identification and shortlisting of a panel of peptides showing promising cell-based activity and extended stability in two distinct types of biological media, the program has identified its first peptide with clear "in vivo" activity in a rat model of inflammatory pain. This pre-clinical peptide has demonstrated effectiveness in alleviating moderate inflammatory pain after administration of a single dose. It is planned to test other shortlisted peptides from the panel for their analgesic activity in the in vivo rat model.

This outcome highlights the potential of appropriately designed, opioid-receptor selective peptides in alleviating pain.

PreveCeutical's President and Chief Science Officer, Dr. Mak Jawadekar, stated, "This novel peptide has the potential for further development as a non-addictive analgesic drug candidate, based on the 'pre-clinical' animal studies that have been conducted so far."

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

PreveCeutical aims to be a leader in preventive health sciences. The Company's current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders.; Nature Identical™ peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter and Facebook.

On Behalf of the Board of Directors

"Dr. Makarand (Mak) Jawadekar"
President & Chief Science Officer

For further information, please contact:

InvestorRelations
IR@PreveCeutical.com  

2987 Postings, 3565 Tage GoldenStockMeine Zielzone

 
  
    #203
29.04.20 21:21
hier liegt noch immer bei 0,20-0,30 Cent für einen Exit, bzw. Gewinnmitnahme.
Mal sehen, wann wir diese Kurse sehen ?? Man braucht wohl etwas Geduld :-)

 

2987 Postings, 3565 Tage GoldenStockCovid-19 ?? PREV ? News

 
  
    #204
04.05.20 20:04
PreveCeutical Announces Possible Viral Prevention Program Using CBD Sol-gel
C.PREV

Vancouver, British Columbia--(Newsfile Corp. - May 4, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it is working on an extension to its successful cannabis sol-gel program to address the COVID-19 pandemic (the "Program Extension"). The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

The focus of the Program Extension will be on the expedited development of a cannabidiol (CBD) sol-gel, at GMP standards, to potentially reduce the possibility of coronavirus infections, including the current COVID-19. Independent researchers in Southern Alberta have provided a detailed medical journal report.

Although a global effort towards developing a safe and effective vaccine for COVID-19 is underway, the vaccine is anticipated to take at least 1-2 years to develop and go into production, and to meet global demands.

With the Company's success in formulating cannabis extract sol-gel formulations in its CBD Sol-gel program, it is uniquely placed to develop and commercialize a CBD sol-gel formulation which the Company believes may reduce the possibility of contracting coronavirus infections ahead of any vaccines reaching the market.

The Company's CBD Sol-gel program has successfully achieved significant milestones, including:

   Extraction and chemical fingerprinting of cannabis extracts (news releases on September 4, 2018, and November 5, 2018).

   Infusion of cannabis extracts, acid and neutral CBD forms (news release November 20, 2018), into wholly water-based sol-gels, using FDA approved excipients (news release July 9, 2019).

   Effective delivery and sustained retention of the cannabis extract infused sol-gels from the nasal spray applicator to the nasal cavity (news release November 19, 2018).

   Confirmed safety of the cannabis extract infused sol-gels when applied to freshly explanted human mucosal tissue, with no elevation in clinically accepted biomarkers of acute toxicity (news release on January 8, 2020).

PreveCeutical has been working on the CBD sol-gel program since September 2017 and has spent over $750,000 in research, not including management and employee overheads.

PreveCeutical is currently working on terms of the Program Extension with partners, and PreveCeutical anticipates formulation development getting underway in the next few weeks. As extensive work on the CBD sol-gel formulation has already taken place, the Program Extension, which has the potential of developing a wholly water-based CBD sol-gel formulation and nasal applicator to reduce the possibility of coronavirus infections, is planned on being ready for testing in as little as four months.

PreveCeutical plans on engaging with global health agencies to seek fast track approval of the CBD sol-gel formulations resulting from the Program Extension.

Although PreveCeutical believes that any such intentions, plans, estimates, beliefs and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs and expectations will prove to be accurate. Researchers say while clinical trials still need to be done, data they have been collecting over the past few years shows promise that some cannabis extracts may help in the prevention and treatment of COVID-19.

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

PreveCeutical aims to be a leader in preventive health sciences. The Company's current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders.; Nature Identical™ peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.

On behalf of the Board of Directors of PreveCeutical

Stephen Van Deventer, Chairman and Chief Executive Officer

For further information, please contact:

Stephen Van Deventer at telephone: +1 604 306 9669

Or Investor Relations ir@preveceutical.com  

2987 Postings, 3565 Tage GoldenStockPREV !! Einfach mal laufen..

 
  
    #205
04.05.20 20:18
lassen.

Bis 0,30  - oder 0,50 Euro ???

Wir werden sehen..... Good Luck !  

2987 Postings, 3565 Tage GoldenStockWerde mal bei 0,30

 
  
    #206
04.05.20 20:23
mein Einsatz rausnehmen die nächsten Tage, hoff PREV läuft bis dahin, nach dieser
COVID-19 News.... Es kann alles passieren -  in diesen verrückten Zeiten.
Rest irgendwo über 0,50 als Gewinn rausnehmen (erstmal) !! Viel Glück.
Kann aber auch sein - das ich daneben liege - und der Kurs nicht soweit ansteigt - wir werden sehen.  

125 Postings, 3137 Tage Chris-Chris37% am Freitag

 
  
    #207
15.06.20 09:06
Ob hier jemand mehr weiß oder das noch der Corona-Solgel-Hype ist? Aber dann wäre er ja fast ne Woche zeitversetzt gekommen?  

2987 Postings, 3565 Tage GoldenStockBin auch gespannt was hier noch kommt,

 
  
    #208
15.06.20 11:42
und wenn hier "DIE" Supernews kommt bei Prev - mit der staatlichen Förderung  30 Mio Dollar,
die am Freitag enschieden werden soll, ob die PREV erhält,  ( was ich gelesen habe ) und eine Partnerschaft mit einem großen
Pharmaunternehmen ebenfalls ansteht, dann kann hier vieles passieren mit dem Kurs.
Von meinen gewünschten :-) 0,30 Cent - bis sogar 3  Euro je Aktie - alles kann/ist/durchaus  möglich sein.
Wer weiß das schon. Ich bleib Long, und schau mal was die nächsten Tage an News so kommen.  

2987 Postings, 3565 Tage GoldenStockBeispiel

 
  
    #209
15.06.20 11:45
was ich auch gelesen,gefunden habe z.B. die Aktie MedMira. Ähnliches Geschäftsfeld wie PREV.
Von 0,01 Cent auf 0,50 Cent in gut 3 Monaten - auch wegen super guten Newsflow usw.
Kann/Könnte das bei PREV auch passieren ???  

125 Postings, 3137 Tage Chris-ChrisHandelssaussetzung: Pending News

 
  
    #210
22.06.20 17:02

125 Postings, 3137 Tage Chris-Chrisa Potential Treatment for SARS-CoV-2 Infection

 
  
    #211
22.06.20 18:44
PreveCeutical Executes Agreement for Development of CBD Sol-Gel Nasal Spray Formulation as a Potential Treatment for SARS-CoV-2 Infection
https://ceo.ca/@newsfile/...cal-executes-agreement-for-development-of  

125 Postings, 3137 Tage Chris-ChrisHandelswiederaufnahme um 19:30 Uhr

 
  
    #212
22.06.20 19:12

2987 Postings, 3565 Tage GoldenStockKanada heute Feiertag am 01.07.

 
  
    #213
01.07.20 17:50
Aber OTC schaut nicht schlecht aus heute - mit + 12 % auf 0,046$.
Langsam ernährt sich das Einhörnchen.
Und irgendwann kommen die NEWS auf die wir alle warten mit Pharmakonzernen usw. und SOL-GEL,
und wir stehen urplötzlich bei 0.50 $ oder sogar 1.00 $ .
Wir warten einfach ab was die nächsten Wochen so passiert hier :-) *g*. Viel Glück.  

2987 Postings, 3565 Tage GoldenStockMittelfristig und bei

 
  
    #214
01.07.20 18:23
bombastischen News das nächste HALBE JAHR - bis Weihnachten - kann ich mir auch Kurse
über 2 $ Dollar  bei PREV vorstellen! Ich hoffe das hier bald bahnbrechende News kommen.
Die Lösungen und  Entwicklungen stehen bereit - es fehlt nur noch Partnerschaften und Produkten.
Auf geht´s PREV !!  

Seite: < 1 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
>  
   Antwort einfügen - nach oben